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Abstract
Background Chronic anal ﬁssure (CAF) is a painful
condition that is unlikely to resolve with conventional
conservative management. Previous studies have reported
that topical treatment of CAF with glyceryl trinitrate
(GTN) reduces pain and promotes healing, but optimal
treatment duration is unknown.
Methods To assess the effect of different treatment
durations on CAF, we designed a prospective randomized
trial comparing 40 versus 80 days with twice daily topical
0.4% GTN treatment (Rectogesic
, Prostrakan Group).
Chronicity was deﬁned by the presence of both morpho-
logical (ﬁbrosis, skin tag, exposed sphincter, hypertrophied
anal papilla) and time criteria (symptoms present for more
than 2 months or pain of less duration but similar episodes
in the past). A gravity score (1 = no visible sphincter;
2 = visible sphincter; 3 = visible sphincter and ﬁbrosis)
was used at baseline. Fissure healing, the primary endpoint
of the study, maximum pain at defecation measured with
VAS and maximum anal resting pressure were assessed at
baseline and at 14, 28, 40 and 80 days. Data was gathered
at the end of the assigned treatment.
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DOI 10.1007/s10151-010-0604-1Results Of 188 patients with chronic ﬁssure, 96 were
randomized to the 40-day group and 92 to the 80-day
group. Patients were well matched for sex, age, VAS and
ﬁssure score. There were 34 (19%) patients who did not
complete treatment, 18 (10%) because of side effects. Of
154 patients who completed treatment, 90 (58%) had their
ﬁssures healed and 105 (68%) were pain free. There was no
difference in healing or symptoms between the 40- and the
80-day group. There was no predictor of ﬁssure healing. A
low ﬁssure gravity score correlated with increased resolu-
tion of pain (P\0.05) and improvement of VAS score
(P\0.05) on both univariate and multivariate analysis. A
lower baseline resting pressure was associated with better
pain resolution on univariate analysis (P\0.01). VAS at
defecation and ﬁssure healing signiﬁcantly improved until
40 days (P\0.001), while the difference between 40 and
80 days was not signiﬁcant.
Conclusion We found no beneﬁts in treating CAF with
topical GTN for 80 days compared to 40 days. Fissure
healing and VAS improvement continue until 6 weeks of
treatment but are unlikely thereafter.
Keywords Anal ﬁssure  Nitric oxide  Nitroglycerin 
Anal pain
Introduction
Chronic anal ﬁssure (CAF) is characterized by a long
duration of symptoms and by pathologic features such as
induration, skin tag, exposed sphincter or hypertrophied
anal papilla [1]. CAF is unlikely to heal with conventional
conservative management such as bulking agents and ‘‘sitz
baths’’ and traditional treatment for chronic ﬁssure is sur-
gical sphincterotomy [2]. Incidence of minor incontinence
to ﬂatus and liquid stool after surgical sphincterotomy
ranges from 8 to 35% [3, 4], and a medical alternative to
sphincterotomy is highly desirable.
Previous studies have reported rapid pain relief and
success in healing acute and chronic anal ﬁssures using
topical nitrates [5, 6]. Acute ﬁssures have a high rate of
spontaneous healing; therefore, most of the reports on the
use of topical nitrates that followed these initial observa-
tions focused on chronic ﬁssures. According to the last
Cochrane review, the effect on healing of chronic ﬁssures
was marginally better than placebo and a high spontaneous
healing rate was observed [7]. In all the examined studies, a
long ([6 weeks) duration of symptoms was considered a
sufﬁcient inclusion criteria irrespective of ﬁssure appear-
ance. Inclusion of patients with acute-type ﬁssures may be
possible and may in part explain the high healing rate
observed in placebo-treated patients. In a study by
Scholeﬁeld et al. [8] when a subset of ﬁssures with more
then one pathologic feature of chronicity were analyzed,
healing rate with placebo dropped to 24% and difference
between nitrates and placebo became signiﬁcant.
Other potentially relevant factors such as dose of
nitrate and treatment duration should also be taken into
account. Dose of nitrate appears to inﬂuence healing rate:
Watson and colleagues suggested that a concentration of
at least 0.3% GTN is necessary to provide adequate
internal sphincter relaxation and allow healing [9]. In a
dose escalating study, optimal GTN concentration for
symptomatic relief was 0.4% [10]. No study to date has
compared different treatment durations. In a prospective
cohort study using topical isosorbide dinitrate Schouten
et al. [11] found that ﬁssure healing rate increased with
treatment duration. Healing rate was 35% at 6 weeks and
88% at 12 weeks. Higher healing rate at 10 weeks (89%)
vs. 5 weeks (67%) is also documented in a randomized
trial of sphincterotomy vs. isosorbide dinitrate [12].
Compliance with treatment may become a problem out of
trials, however, and a minimum length of time for
treatment while maintaining efﬁcacy is desirable. The
aim of this study was to observe the effect of duration of
treatment with topical GTN on healing of and pain from
CAF.
Patients and methods
The study was a prospective randomized open label mul-
ticenter trial. Inclusion criteria were any of the following:
presence of induration (ﬁbrosis), skin tag, visible internal
anal sphincter ﬁbers or hypertrophied anal papilla. In
addition to morphological criteria duration of symptoms
for more than 2 months [1] or with pain of less duration but
similar episodes in the past was required. Exclusion criteria
were age \18, nitrate medications, history of orthostatic
hypotension, history of recent (\2 months) anal surgery,
pregnancy, contraindications or intolerance to nitrates,
ﬁssure off-midline, inﬂammatory bowel disease or ﬁssure
secondary to an underlying disease e.g., HIV, tuberculosis,
syphilis.
Eleven Coloproctology Units currently registered with
the Italian Society of Colorectal Surgery (SICCR) partici-
pated in the study. The study received ethical approval by
the SICCR Trial Review Board and was performed in
accordance with the Declaration of Helsinki. All the
patients gave written informed consent for participation in
the study.
Aluminum tubes containing 0.4% GTN ointment
(Rectogesic
, Prostrakan Group) were provided by the
Pharmaceutical Company free of charge. Each patient was
instructed to squeeze out of the tube 2.5 cm of GTN
ointment (a measuring line was printed on the product),
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123which corresponds to approximately 1.5 mg of GTN, and
to apply it twice daily with a gloved ﬁnger to the distal anal
canal. Patients were also encouraged to prevent hard stool
with dietary measures and to expect and report speciﬁc side
effects. Baseline assessment included duration of symp-
toms, worse pain on a VAS scale at defecation, anal
examination with assessment of ﬁbrosis, exposed sphincter
and hypertrophic papilla (e). Manometry was performed if
tolerated by the patient. Investigators were instructed to
record only the maximum resting pressure (MRP) along the
anal canal in mmHg using the manometry equipment
available in their facility. Technical details on different
methods of acquisition of resting pressure were not asses-
sed. Follow-up visits were scheduled at 2, 4, 6 and 8 weeks
and 80 days and included assessment of symptoms and
compliance, worse pain on a VAS scale at defecation and
anal examination. Compliance was based on patient’s
report and assessed at each visit. Patients applying the
prescribed amount of GTN at least 12 times per week were
considered compliant. Fissures were scored 0 to 3 (grade
0 = no ﬁssures; grade 1 = ﬁssure with no visible sphincter
or ﬁbrosis; grade 2 = ﬁssure with visible sphincter without
ﬁbrosis and grade 3 = ﬁssure with visible sphincter and
ﬁbrosis). In monitoring side effects, headache was not
graded, and dizziness was deﬁned as either severe light-
headedness, severe muscle weakness or orthostatic
hypotension.
Patients were randomized to either 40 days (6 weeks)
treatment or 80 days (12 weeks) of topical GTN treatment.
Calculated sample size was 81 patients per arm based on an
expected healing rate of 70% to detect a 20% difference at
P\0.05 level with b set at 0.1 using Pocock’s formula.
Taking into account a drop-out rate of 10%, total number
of 178 was estimated as sufﬁcient to close the study.
Randomization was performed in computer-generated
blocks and concealed in opaque sealed envelopes. Partici-
pating physicians were not aware of block size.
Statistical analysis
Fissure healing and resolution of evacuatory pain are cat-
egorical variables, so we performed a multivariate logistic
regression model with stepwise selection of independent
variables. Each of the two outcomes was analyzed both by
multivariate analysis of data at the end of treatment
(according to assigned treatment) and after the crossover of
9 patients by 40-day treatment to 80-day treatment group
(according to treatment protocol). All baseline variables
are included in the initial model as independent covariates.
The signiﬁcance level for entering in the model was 0.20.
Treatment allocation, sex and age were forced to enter the
model as adjustment variables even if not statistically
signiﬁcant. The effect of independent variables on the
outcomes was measured by odds ratio (OR) estimates and
95% conﬁdence interval (CI).
We used linear mixed models to analyze the temporal
variations of pain measured by VAS, the timing of ﬁssure
healing and of pain resolution. Linear mixed model allows
repeated measures analysis in the presence of missing
values, assuming that the values are missing at random.
The set of covariates that determined the model with the
lowest Akaike Information Criterion were included in the
model with observation time point, sex and age. The results
were expressed through the mean and standard deviation
determined by the least squares estimate.
We also carried out multiple comparisons to assess the
difference of VAS, ﬁssure healing and resolution of evac-
uatory pain between consecutive observation time point;
P-values were adjusted for multiple comparisons according
to the Tukey–Kramer method.
Statistical analyses were performed using SAS software
Version 9.2 for PC.
Results
Between March 2007 and November 2008, 188 patients
were enrolled, 96 in the 40-day group and 92 in the 80-day
group. At baseline, the only characteristic that differed
between groups was the presence of skin tags, which were
more frequent in the 80-day group (Table 1). There were 2
patients with a painless chronic ﬁssure, both in the 40-day
treatment group. Neither of these 2 patients healed their
ﬁssure, and one developed mild pain (VAS = 2) in the
course of the treatment. Of 188 patients initially enrolled,
34 (19%) either discontinued treatment (n = 27) or were
lost to follow-up (n = 7), 21 in the 40-day group and 13 in
the 80-day group (P = 0.42). Reasons for discontinuation
of treatment were side effects in 15 (8%), worsening
symptoms in 9 (5%) and a combination of both in 3 (2%).
Headache and dizziness were the only side effects noted
(Table 2). A ﬂow chart with the results of the study is
shown in Fig. 1.
Healing of ﬁssure
According to the intention to treat and considering drop-
outs as failures, 41 (43%) patients had their ﬁssures
Table 1 Side effects
Did not complete study
(n = 34) number of
patients (%)
Completed study
(n = 154) number
of patients (%)
Headache 15 (44) 35 (23)
Dizziness 1 (3) 3 (2)
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123completely healed in the 40-day group vs. 42 (46%) in the
80-day group (P = 0.77). Of the 154 patients who com-
pleted treatment, 41 of 75 (55%) patients in the 40-day
group and 42 of 79 (53%) patients in the 80-day group had
their ﬁssures healed (P = 0.87). At the end of the 40-day
treatment, 9 patients crossed over from the 40- to the
80-daygroup.Bytheendoftheﬁrst40 days,3of9crossover
patients were free of pain but with a persistent ﬁssure and 6
Table 2 Patient’s
characteristics according to
randomization group for all
(n = 188) patients enrolled
VAS visual analogue score,
MRP maximum resting pressure
# Chi square for independence
a MRP was available in 150 of
188 patients
40 days 80 days P
n (% or ±SD) n (% or ±SD)
Age 51.5 (±12) 49.3 (±12.6) 0.238
Male 51 (51) 49 (49) 0.985
Female 45 (51.1) 43 (48.9)
Duration of symptoms weeks 12.54 (±13.6) 13.6 (±24.9) 0.714
Randomization 96 (51.1) 92 (48.9)
Fibrosis 63 (54.8) 52 (45.2) 0.200
No ﬁbrosis 45.2% (n.33) 54.8 (n.40)
Exposed sphincter 67 (47.5) 74 (52.5) 0.092
No exposed sphincter 29 (61.7) 18 (38.3)
Skin tag 43 (43.4) 56 (56.6) 0.027
No skin tag 53 (59.6) 36 (40.4)
Hypertrophied anal papilla 44 (51.8) 41 (48.2) 0.861
No hypertrophied anal papilla 52 (50.5) 51 (49.5)
Fissure gravity score 2.16 (±0.85) 2.30 (±0.78) 0.216
VAS at defecation 7.49 ± 1.99 7.59 ± 1.48 0.674
MRP
a 105.83 (±22.02) 99.91 (±23.44) 0.113
Grade 1 28 (61) 18 (39) 0.3072
#
Grade 2 25 (47) 28 (53)
Grade 3 43 (48) 46 (52)
Similar past episodes 48 (50) 49 (53.3) 0.655
No past episodes 48 (50) 43 (46.7)
Fig. 1 Treatment ﬂow chart
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123reportedsymptomaticimprovementfromanaverageVASof
8.1 (±0.1 SD) to an average VAS of 4.5 (±2 SD). All 9
crossover patients healed their ﬁssure after 80 days of
treatment. Results of the univariate analysis for ﬁssure
healing in the 154 patients who completed the assigned
treatment are shown in Table 3. There was no variable that
signiﬁcantly predicted ﬁssure healing after GTN treatment.
Similarly, on multivariate analysis according to assigned
treatment and per treatment protocol, no variable was inde-
pendently predictive of ﬁssure healing.
Resolution of pain
According to intention to treat and considering drop-outs as
failures, 43 of 96 (45%) patients in the 40-day group and 53
of 92 (58%) patients in the 80-day group were free of pain
at defecation by the end of the study (P = 0.08). After
eliminating the 35 who discontinued treatment, there were
43 of 75 (57%) pain-free patients in the 40-day group and
53 of 79 (67%) pain-free patients in the 80-day group
(P = 0.24). Including the 9 patients who crossed over from
the 40-day group to the 80-day group, a total of 105 (68%)
compliant to GTN treatment were free from pain. The
results of the univariate analysis for resolution of evacu-
atory pain according to assigned treatment are shown in
Table 4. Persistence of pain was associated with ﬁbrosis
(P = 0.018), high maximum resting pressure (P = 0.0128)
and high ﬁssure gravity score (P = 0.036).
On multivariate analysis according to assigned treat-
ment, a low ﬁssure gravity score (OR = 0.034, 95% CI
0.004–0.277) was the only independent predictor of pain
resolution. When multivariate analysis was carried out
according to treatment protocol, treatment assignment to
the 80-day group (OR = 2.757, 95% CI 1.147–6.630) and
low ﬁssure score (OR = 0.053, 95% CI 0.007–0.401) were
independent predictors of pain resolution (Table 5).
Changes in VAS score
Of the154 patients whocompleted thestudy,150 (97%)had
symptomatic improvement as measured by the VAS score.
Of the 49 patients with residual pain at the end of the study,
45 improved by a mean of 4.1 points (±1.74 SD) on a VAS
scaleof1to10.Whenthelinearmixedmodelwasappliedto
analyze factors signiﬁcantly correlated with a change of
VAS score, an initial ﬁssure gravity score of 1 (esti-
mate =- 0.6003; standard error = 0.3000; P = 0.0472)
and initial ﬁssure gravity score of 2 (estimate =- 1.1806;
standard error = 0.2762; P =\0.0001) were signiﬁcantly
correlated with improvement of the VAS score over time.
Changes in VAS score during GTN treatment are shown in
Fig. 2. VAS score decreased signiﬁcantly and progressively
Table 3 Results of univariate
analysis for ﬁssure healing in
154 patients according to
intention to treat after
eliminating 34 patients who
discontinued the study
VAS visual analogue score,
MRP maximum resting pressure
# Grade 1 vs. Grade 3;
¥Grade 2
vs. Grade 3
a MRP was available in 118 of
154 patients
Healed n (% or ±SD) Did not heal n (% or ±SD) P
Age 49.7(11.4) 50.00 (13.6) 0.895
Male 44 (53) 39 (47) 0.812
Female 39 (55) 32 (45)
40 days 41 (55) 34 (46) 0.852
80 days 42 (54) 37 (47)
Duration of symptoms weeks 15 (28.2) 12 (8.8) 0.290
Fibrosis 48 (52) 45 (48) 0.483
No ﬁbrosis 35 (58) 26 (42)
Exposed sphincter 60 (52) 57 (48)
No exposed sphincter 23 (63) 14 (37)
Skin tag 42 (54) 37 (46) 0.852
No skin tag 41 (55) 34 (45)
Hypertrophied anal papilla 33 (51) 33 (49) 0.401
No hypertrophied anal papilla 50 (57) 38 (43)
Fissure gravity score 2.14 (0.82) 2.31 (0.78) 0.208
VAS at defecation 7.367 (1.647) 7.641 (1.946) 0.3466
MRP mmHg
a 100.16 (1.352) 107.24 (25.345) 0.103
Grade 1 23 (62) 14 (38) 0.2277
#
Grade 2 21 (46) 25 (54) 0.7053
¥
Grade 3 35 (49) 36 (51)
Similar past episodes 39 (48) 42 (52) 0.132
No past episodes 44 (60) 29 (40)
Tech Coloproctol (2010) 14:241–248 245
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niﬁcant improvement in VAS pain score was observed.
Timing of ﬁssure healing
Healing of ﬁssure over time is illustrated in Fig. 3. Healing
increased signiﬁcantly and progressively through the trial
until after 6 weeks when no further signiﬁcant improve-
ment in numbers of ﬁssures healed was observed.
Timing of pain resolution
Resolution of pain over time is illustrated in Fig. 4. There
was a signiﬁcant increase in the number of patients whose
pain resolved between base line and 2 weeks (P\0.001),
2 weeks and 4 weeks (P\0.001), 4 weeks and 40 days
(P\0.001) and between40 days and 80 days (P = 0.007).
Discussion
Our study is the ﬁrst trial that addresses treatment duration
with GTN ointment in chronic anal ﬁssure. Our results
show that an 80-day (12 weeks) topical GTN course is not
superior to a 40-day (6 weeks) course when healing and
pain are taken as endpoints. Our deﬁnition of chronic anal
ﬁssure was more stringent than any other published study,
since it included both anatomic features of chronicity and
duration of symptoms. Our overall success rate in healing
chronic ﬁssure was of 43% (which includes a 20% drop-out
rate). Of the patients who did not complete the study, half
of them had unwanted side effects, while the other half had
persistent unresolved pain. Among patients who completed
the study, ﬁssure healing rate was 58% and a complete
symptomatic response was seen in 68%, in line with pre-
vious randomized controlled trials [7].
The majority of compliant patients had a consistent and
progressive decrease of pain at defecation measured by the
Table 4 Results of univariate
analysis for resolution of pain in
154 patients according to
intention to treat after
eliminating 34 patients who
discontinued the study
VAS visual analogue score,
MRP maximum resting pressure
# Grade 1 vs. Grade 3;
¥Grade 2
vs. Grade 3
a MRP was available in 118 of
154 patients
Pain resolved Pain persisted P
n (% or ±SD) n (% or ±SD)
Age 48.5 (11.7) 52.02 (13.3) 0.093
Male 53 (64) 30 (36) 0.674
Female 43 (61) 28 (39)
40 days 43 (58) 32 (42) 0.212
80 days 53 (68) 26 (32)
Duration of symptoms weeks 12.45 (25.9) 14.72 (11.5) 0.528
Fibrosis 51 (55) 42 (45) 0.018
No ﬁbrosis 45 (74) 16 (26)
Exposed sphincter 72 (62) 45 (38) 0.716
No exposed sphincter 24 (65) 13 (35)
Skin tag 51 (65) 28 (35) 0.560
No skin tag 45 (60) 30 (40)
Hypertrophied anal papilla 40 (60) 26 (40) 0.701
No hypertrophied anal papilla 56 (64) 32 (36)
Fissure gravity score 2.11 (0.78) 2.40 (8.37) 0.036
VAS at defecation 7.380 (1.729) 7.681 (1.889) 0.3139
MRP mmHg
a 98.931 (20.063) 109.77 (26.468) 0.0128
Grade 1 24 (65) 13 (35) 0.1552
#
Grade 2 37 (80) 9 (20) 0.0009
¥
Grade 3 35 (50) 36 (50)
Similar past episodes 49 (65) 26 (35) 0.5075
No past episodes 47(59) 32 (41)
Table 5 Multivariate analysis for factors correlated with persistence
of defecatory pain in the 154 patients who completed treatment
Odds Ratio (OR) and 95% Conﬁdence Intervals (CI)
Variable Intention to treat Per treatment
OR 95% CI OR 95% CI
Age 1.016 0.981 1.052 1.000 0.967 1.034
40 days vs. 80 days 2.045 0.860 4.862 2.757 1.147 6.630
Male vs. female 0.594 0.246 1.435 1.063 0.454 2.491
Presence of ﬁbrosis 0.214 0.039 1.189 0.195 0.037 1.040
Fissure grade 1 vs. 3 0.289 0.076 1.100 0.478 0.133 1.726
Fissure grade 2 vs. 3 0.034 0.004 0.277 0.053 0.007 0.401
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average of 8 (95% CI 7–10) to an average below 1 (95% CI
0–7) in 150 (97%) of the patients who completed the study
(Fig. 2). Ours is the ﬁrst clinical trial that used the 0.4%
concentration of GTN twice daily, which was found to be
the most effective in a dose escalating trial [10]. This
concentration is also commercially available and therefore
easily used out of a trial setting.
The optimal treatment duration for topical GTN was
6 weeks. Ours is the ﬁrst prospective study monitoring the
effects of topical GTN treatment for longer than 8 weeks.
Resolution of pain, ﬁssure healing and VAS continue to
improve signiﬁcantly until 6 weeks. If by 6 weeks the
ﬁssure has not healed, treatment with GTN ointment should
be discontinued, and the patient should be referred to a
surgeon for sphincterotomy that has shown to be successful
in patients failing GTN treatment [13]. Some reports have
shown healing of the ﬁssure after failed GTN treatment
with other topical agents [14] or with botox injection [15].
A possible exception to this algorithm may be in patients
who have shown considerable improvement after GTN
treatment. In our trial, 9 of such patients were allowed to
cross over to the 80-day group, and all of them healed their
ﬁssure (Fig. 1). This is reﬂected in the data analysis after
crossover that showed the 80-day course to be superior to
the 40-day course in obtaining complete symptomatic
resolution.
Of the 154 patients who completed the trial, 23% suf-
fered from headache and 2% from dizziness, while of the
34 who discontinued treatment, 44% suffered from head-
ache and 3% from dizziness (Table 1). Our rate of side
effects is similar to other studies that used different GTN
concentration [9, 10, 16]. If headache or dizziness were
present, patients were instructed to apply the ointments
while lying down or to take paracetamol before GTN
application. Patient counseling on expecting, preventing
and treating the possible side effects of topical GTN is an
important part of the treatment.
In our multivariate analysis, we found that ﬁssures with
a high severity score, which include ﬁssures with both an
exposed sphincter and ﬁbrosis, were less likely to have a
symptomatic response even after a long course of GTN. A
high resting pressure was correlated with persistence of
symptoms on univariate analysis, but manometry data was
not available in all patients and could not be included in the
multiple regression model. Patients with both ﬁbrosis and
exposed sphincter (grade 3) were 46% of compliant
patients, and 50% of them healed their ﬁssure (Table 3).
Therefore, while we think that these patients should be
closely monitored and treatment promptly changed after a
6 weeks of GTN, we do not think that GTN should be
automatically excluded from their treatment algorithm.
This group of patients should be adequately counseled
about risk and beneﬁts of various treatment options.
In conclusion, the treatment response of CAF to topical
GTN continues to improve until 6 weeks after which there
is no additional beneﬁt observed. Fissures with both
ﬁbrosis and exposed sphincter ﬁbers are less likely to
respond to GTN treatment. This should be taken into
account when counseling patients with CAF.
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